Given that KRAS G12C inhibitors did not result in good response rates for colorectal cancer patients in clinical trials,[33] we conducted in vivo evaluation of the combined KRAS G12C and FAK inhibition therapy using two CRC PDX models: CO‐04‐0315 and CO‐04‐0070. This evidence concerns the gene PTK2 and colorectal carcinoma.